ASIA News
The solution screens for plus disease, which is associated with severe ROP.
Individuals are also less likely to trust AI-suggested interventions than those recommended by humans.
The company will maintain its patent right for the technology.
Docquity will use its fresh funds to further expand into East Asia and the Middle East.
Also, Lunit has received Taiwan's approval for its AI mammography solution.
It will use its fresh funds to complete a multi-site validation study across eight Asia-Pacific markets.
Dozee's sensor-based technology uses AI to track vital parameters.
It will be used to accelerate collaborations with pharmaceutical firms.
It will use its latest funds for its global expansion.
Also, CureApp is getting $77 million in investment from the Sawai Group as part of their license deal.